Role of the Renin-Angiotensin System in the Control of Vasopressin and ACTH Secretion during the Development of Renal Hypertension in Dogs

LILLIAN K. BEN, B.S., JUDY MASELLI, B.S., LANNY C. KEIL, PH.D., AND IAN A. REID, PH.D.

SUMMARY Experiments were performed to determine if the activation of the renin-angiotensin system that occurs during the development of two-kidney, one clip Goldblatt hypertension in dogs is accompanied by increases in vasopressin and adrenocorticotrophic hormone (ACTH) secretion. Following renal artery constriction, there were marked increases in arterial blood pressure, plasma renin activity (PRA), and plasma angiotensin II (All) concentration. These changes were accompanied by an increase in plasma vasopressin concentration during the second week following constriction, and there were significant correlations between plasma vasopressin concentration and PRA (r = 0.57, \( p < 0.001 \)), and between plasma vasopressin concentration and plasma All concentration (r = 0.59, \( p < 0.001 \)). In contrast, plasma corticosteroid concentration, used as an index of changes in ACTH secretion, did not change significantly. Acute blockade of the renin-angiotensin system with captopril or saralasin produced the expected changes in blood pressure, PRA, and plasma All concentration but did not decrease plasma vasopressin or corticosteroid concentrations. These results indicate that during the development of renal hypertension in dogs, there may be an interaction between the renin-angiotensin system and vasopressin, but not between the renin-angiotensin system and the pituitary-adrenal axis. They also show that the antihypertensive action of captopril in this experimental model is not mediated via suppression of vasopressin, ACTH, or corticosteroid secretion. (Hypertension 6: 35-41, 1984)

KEY WORDS • angiotensin II • captopril • saralasin • pituitary • corticosteroids

THE activity of the renin-angiotensin system is increased in a variety of forms of experimental and human hypertension.\(^1\) Administration of agents that block the formation or actions of angiotensin II (All) lowers blood pressure in these hypertensive states, indicating that the hypertension is dependent, at least in part, on the renin-angiotensin system.\(^1\)\(^2\)

The hypertensive action of All is largely the result of its direct action to constrict vascular smooth muscle. However, All may also influence arterial pressure by a number of indirect mechanisms. For example, it is known to stimulate the secretion of vasopressin and adrenocorticotrophic hormone (ACTH),\(^3\)\(^5\) two peptides that can have marked effects on blood pressure.\(^6\)\(^7\) It is therefore possible that the elevated All levels in some hypertensive states increase the secretion of vasopressin and ACTH, which in turn act to increase blood pressure. Moreover, it is possible that the antihypertensive effect of blockade of the renin-angiotensin system is partly due to inhibition of the stimulatory action of All on vasopressin and ACTH secretion.

The present experiments were designed to test these possibilities. This was accomplished by monitoring the plasma levels of renin, All, vasopressin, and corticosteroids (used as an index of ACTH secretion) during the development of two-kidney, one clip Goldblatt hypertension in dogs. In addition, the effect of blockade of the renin-angiotensin system with captopril or saralasin on the secretion of these hormones was studied at different times during the development of hypertension.

Methods

The experiments were performed on five mongrel dogs of both sexes, weighing 18–34 kg. They had free access to water and were fed a diet of Purina dry dog chow (Ralston Purina Company, St. Louis, Missouri), which provided approximately 80 mEq sodium/day. Under sodium pentobarbital anesthesia (30 mg/kg, \( \text{by guest on July 12, 2017 http://hyper.ahajournals.org/ Downloaded from} \)

\(^{1}\) From the Department of Physiology, University of California at San Francisco, San Francisco; and the Ames Research Center, Moffett Field, California.

\(^{2}\) Supported by USPHS Grant AM06704.

\(^{3}\) Address for reprints: Ian A. Reid, Ph.D., Department of Physiology 762-S, University of California at San Francisco, San Francisco, California 94143.

\(^{4}\) Received June 22, 1983; revision accepted August 3, 1983.
i.v.), Tygon cannulas (0.5 mm i.d.) were chronically implanted in a femoral artery and vein. Both cannulas were led subcutaneously to a point between the shoulders where they were exteriorized and protected by a vest (Medical Arts, Los Angeles, California). On alternate days, the cannulas were flushed with sterile isotonic saline and filled with heparinized saline (1000 U/ml). During the 4 days following surgery, the dogs were treated with penicillin and streptomycin (Combiotic, Pfizer, New York, 3.0 ml/day). At least 2 days were allowed for recovery.

Following recovery from surgery, the dogs were brought to the laboratory on at least two occasions for control measurements. In the laboratory the dogs were allowed to stand while loosely restrained by a sling (Medical Arts, Los Angeles, California). Mean and pulsatile blood pressure and heart rate were continuously recorded for at least 30 minutes with a Grass polygraph (Grass Instruments, Quincy, Massachusetts) and a tachograph, which was triggered by the blood pressure pulse wave. Two 12 ml blood samples separated by 30 minutes were collected from the femoral artery and replaced with an equal volume of sterile isotonic saline. All samples were taken at approximately the same time each day (1000 to 1400 hours) in order to minimize possible hormonal changes due to circadian rhythms.

After control measurements had been made, the dogs were anesthetized with sodium pentobarbital. The right kidney was exposed through a flank incision, and a clay-filled ameroid constrictor (Three Points Products, Montreal, Canada) was placed around the renal artery. Following implantation, the ameroid gradually constricts the artery and hypertension results.8 Following surgery, the dogs were again treated with penicillin and streptomycin for 4 days. During the 30-day period following ameroid implantation, the dogs were brought to the laboratory every 2 to 3 days for blood pressure and heart rate recording and collection of blood samples as described above.

The effects of acute blockade of the renin-angiotensin system with a converting-enzyme inhibitor, captopril, or an angiotensin II receptor antagonist, saralasin, were also studied in these animals. The effects of captopril were studied 4–7, 9–14, and 15–21 days following placement of the ameroid. Two control blood samples were collected and then captopril (Squibb) dissolved in sterile isotonic saline was injected i.v. in a single dose of 5.0 mg/kg. Additional blood samples were collected 15, 30, 45, and 60 minutes following the injection. Blood pressure and heart rate were monitored continuously. The effects of saralasin were studied 7–9, 11–14, and 17–23 days following ameroid implantation. After collection of control blood samples, saralasin (Bachem) dissolved in sterile isotonic saline was infused i.v. in a dose of 2.0 μg/kg/min for 30 minutes. Blood samples were collected at 15 min intervals during the infusion and for 30 minutes following cessation of the infusion.

The blood samples were divided into two aliquots: 1) 4.5 ml was added to 0.5 ml 0.3 M EDTA in a chilled centrifuge tube for the determination of PRA and All concentration; 2) the remaining blood was added to a heparinized centrifuge tube for the determination of plasma vasopressin and corticosteroid concentrations and osmolality. The blood samples were centrifuged and the plasma separated and frozen until analysis.

Plasma vasopressin concentration was measured by radioimmunoassay of extracted plasma.9 Plasma corticosteroids were measured by radioimmunoassay,10 and changes in plasma corticosteroid concentration were used as an index of changes in ACTH secretion. Plasma renin activity was measured using a radioimmunoassay for Al and expressed as nanogram AI generated per ml plasma during a 3-hour incubation at 37°C (ng/ml/3 hr).11,12 Plasma AI concentration was measured by radioimmunoassay. Angiotensin II was extracted with the bentonite procedure used for the vasopressin assay.9 The radioimmunoassay was performed as described previously.13 In this assay, displacement of tracer by All extracted from plasma is parallel to that of synthetic AI (Figure 1). The AI antibody used in the assay cross reacts 100% with AI and 10% with AI. The intra- and interassay coefficients of variation average 6.9% and 11.6% respectively. Recovery of angiotensin II during the extraction procedure averages 65% and all values were corrected for this. Plasma osmolality was measured by freezing point depression with a Fiske osmometer (Fiske Associates, Uxbridge, Massachusetts).

All results are expressed as the means ± se. Unless indicated otherwise, statistical evaluation of the data was performed using one-way analysis of variance for repeated measures.14 Values for PRA and plasma AI concentration obtained during the 30-day period following renal artery constriction showed a significant (p < 0.01) positive skewness. This skewness was eliminated by log transformation of the data. Comparisons between specific time points and control values were made using Dunnett’s t test.14

![Standard curve for the angiotensin II radioimmunoassay showing parallel displacement of tracer by extracted plasma.](image-url)
Results

Cardiovascular and Endocrine Changes During the Development of Hypertension

The cardiovascular and endocrine changes that occurred during the development of renal hypertension are summarized in Figure 2. Mean arterial pressure increased progressively from the control value of 118 ± 7 to 166 ± 9 mm Hg on Day 9 (p < 0.01). Blood pressure remained between 149 and 165 mm Hg for the remainder of the 30-day period. There was no significant change in heart rate.

Plasma renin activity increased from the control value of 7.2 ± 2.8 to 51.0 ± 21.2 ng/ml/3 hr on Days 10–12, and remained between 41.2 and 67.8 ng/ml/3 hr for the remainder of the period of observation. Prior to constriction of the renal artery, plasma AI1 concentration averaged 11.1 ± 4.2 pg/ml. It increased to 98.3 ± 44 pg/ml on Days 10–12 (p < 0.01) and remained between 65.7 and 146.9 pg/ml for the remainder of the 30-day period. The changes in plasma AI1 closely paralleled those in PRA (Figure 2) and, overall, there was a very close correlation between these two variables: Plasma AI1 = 2 (PRA) − 6 (r = 0.96, *p < 0.001) (Figure 3). There were also significant correlations between mean arterial pressure (MAP) and PRA (r = 0.77, *p < 0.001) and between MAP and plasma AI1 concentration (r = 0.71, *p < 0.001).

Plasma vasopressin concentration increased by at least 50% in all animals but the time at which the maximal increase occurred varied from animal to animal. However, the maximum always occurred between Days 8 and 16, and the maximal increase from 2.6 ± 0.5 to 5.4 ± 0.5 pg/ml was statistically significant (p < 0.05, paired t test). During the 30-day period, there were significant correlations between plasma vasopressin concentration and plasma AI1 concentration (r = 0.59, *p < 0.001) (Figure 4) and between plasma vasopressin concentration and PRA (r = 0.57, *p < 0.001). There was a lower but statistically significant correlation between MAP pressure and plasma vasopressin concentration (r = 0.37, *p < 0.002).

Plasma corticosteroid concentration, used here to reflect changes in ACTH secretion, did not change significantly. Plasma osmolality also did not change significantly, remaining between 293 and 299 mOsm/kg H2O throughout the whole study.
Effects of Captopril and Saralasin

The cardiovascular and endocrine effects of captopril and saralasin are summarized in Figures 5–7. Administration of captopril between Days 4 and 7 caused a marked fall in arterial pressure from 160 ± 7 to 128 ± 6 mm Hg (p < 0.01) (Figure 5). Heart rate increased from 68 ± 11 to 83 ± 6 bpm (p < 0.05). PRA increased from 15.7 ± 3.3 to a maximum of 136 ± 27.8 ng/ml/3 hr (p < 0.01). Despite this large increase, plasma Ang II concentration did not change significantly, indicating effective blockade of converting enzyme. Neither plasma vasopressin nor corticosteroid concentrations were altered by captopril (Figure 5). Administration of saralasin between Days 7 and 9 had no significant effects on any of the measured variables (Figure 5).

The effects of captopril administration on Days 9–14 were similar to those on Days 4–7 but more marked (Figure 6). Blood pressure decreased from 162 ± 13 to 124 ± 6 mm Hg (p < 0.01) and heart rate increased from 73 ± 11 to 119 ± 15 bpm (p < 0.01). There was a marked increase in PRA from 41.2 ± 19.0 to 208.5 ± 47.5 ng/ml/3 hr (p < 0.01) but, despite this, plasma Ang II concentration actually decreased from 80.6 ± 38.2 to 36.8 ± 23.2 pg/ml (p < 0.05). Plasma vasopressin and corticosteroid concentrations tended to increase following injection of captopril but, overall, there were no statistically significant changes. Administration of saralasin on Days 11–14 tended to decrease blood pressure but, again, this effect was not statistically significant. Heart rate did not change. PRA in-

![Image of Figures 5, 6, and 7]
increased from 46.7 ± 13.7 to 111.5 ± 32.5 ng/ml/3 hr (p < 0.05) and plasma All concentration increased from 68.0 ± 17.9 to 231.4 ± 88.2 pg/ml (p < 0.05). Plasma vasopressin concentration increased from 4.4 ± 0.4 to 6.5 ± 0.3 pg/ml (p < 0.05) but plasma corticosteroid concentration did not change significantly.

The effects of captopril administration between Days 15–21 were generally similar to the responses observed on the other two occasions. Blood pressure decreased from 155 ± 10 to 122 ± 6 mm Hg (p < 0.01) and heart rate increased from 77 ± 11 to 100 ± 11 bpm (p < 0.05). PRA increased from 38.9 ± 18.6 to 237.6 ± 54.5 ng/ml/3 hr (p < 0.01) but plasma All concentration did not change significantly. Plasma vasopressin concentration increased from 3.8 ± 1.0 to 7.9 ± 3.3 pg/ml (p < 0.05) but plasma corticosteroid concentration did not change significantly. Administration of saralasin caused no significant changes in any of the measured variables except for an increase in plasma corticosteroid concentration from 1.2 ± 0.4 to 3.0 ± 0.6 µg/dl (p < 0.05).

The relationship between plasma All concentration and PRA before and after treatment with captopril is shown in Figure 8. Before captopril, the relationship was:

\[
\text{plasma All} = 2 \times (\text{PRA}) - 4 \quad (r = 0.97, \ p < 0.001)
\]

while after captopril, the relationship was:

\[
\text{plasma All} = 0.13 \times (\text{PRA}) + 22 \quad (r = 0.80, \ p < 0.001).
\]

Thus, the slope of the relationship after captopril was only 7% of that before captopril, and this corresponds well to the 10% cross reactivity of the All antibody for AI. This suggests that captopril completely blocked conversion of AI to All and explains why plasma All levels apparently did not decrease to zero following captopril administration.

**Discussion**

The changes in blood pressure, PRA, and plasma All concentration that occurred during the development of two-kidney, one clip hypertension in the present study are generally similar to those observed in other models of renal hypertension. The changes in blood pressure correlated closely with the changes in PRA (r = 0.77) and plasma All concentrations (r = 0.71), suggesting an important role for the renin-angiotensin system in this form of hypertension. As expected, administration of the converting-enzyme inhibitor captopril at different times during the development of renal hypertension produced prompt and marked falls in arterial pressure. In contrast, administration of the All receptor antagonist saralasin produced little change in blood pressure. This discrepancy between the effects of converting-enzyme inhibition and angiotensin receptor blockade has been observed by other investigators and is thought to reflect the intrinsic agonist activity of saralasin and the bradykinin-potentiating action of captopril.

There have been several reports that plasma vasopressin concentration or urinary vasopressin excretion is elevated in animal models of hypertension in which there is increased activity of the renin-angiotensin system. It has also been reported that plasma vasopressin levels are increased in patients with malignant hypertension. Indeed, Thibonnier and associates reported a close correlation between plasma vasopressin concentration and PRA in a group of patients with severe hypertension. In general, the results of the present study confirm and extend these previous findings. Activation of the renin-angiotensin system by constriction of one renal artery led to an increase in plasma vasopressin concentration. The increase in plasma vasopressin concentration was slow to develop, reaching a maximum between Days 8 and 16, when PRA and plasma All concentration were at or near their maximal values. Over the time course of the present study, there were significant correlations between plasma vasopressin concentration and PRA and between plasma vasopressin concentration and PRA and plasma All concentration.

Because it is known that All can stimulate the secretion of vasopressin, it seems reasonable to propose that the increase in plasma vasopressin concentration was mediated via the renin-angiotensin system. The finding of correlations between plasma vasopressin concentration and plasma renin and All levels is consistent with this possibility. On the other hand, blockade of the renin-angiotensin system in hypertensive dogs with either saralasin or captopril failed to decrease plasma vasopressin concentration. Indeed, in some animals, plasma vasopressin levels actually increased following captopril administration, presumably because of the large fall in arterial pressure. Thibonnier et al. also reported that acute administration of captopril in hypertensive patients did not decrease plasma vasopressin concentration. However, they ob-
served significant reductions in both plasma vasopres- 
sin concentration and urinary vasopressin excretion 
during chronic treatment with captopril and this agrees 
well with observations made in rats with spontaneous 
hypertension by Crofton and associates. 23

It is now clear that vasopressin is a potent vasocon-
strictor, 6 and there is considerable evidence that this 
peptide plays an important role in the physiological 
regulation of arterial pressure. 7 10 There is also evidence 
that vasopressin may be involved in the pathogenesis 
of some forms of hypertension, although this point is 
still controversial. 8 24 However, it is unlikely that 
vasopressin contributed in a major way to the devel-
opment of hypertension in the present study because 
plasma vasopressin concentration did not increase sig-
nificantly until the maximum increase in blood pres-
sure had already occurred. Furthermore, there was 
only a weak correlation between plasma vasopressin 
concentration and mean arterial pressure (r = 0.37, p 
< 0.002). Pullan et al. 25 also concluded that it is 
unlikely that vasopressin plays a significant direct pressor 
role in the pathogenesis of one-kidney Goldblatt hy-
pertension in the dog. The present results further dem-
onstrate that the acute antihypertensive action of cap-
tropril is not mediated via inhibition of vasopressin 
secretion. However, reduction in plasma vasopressin 
concentration may become more significant in blood 
pressure regulation during chronic captopril treat-
ment. 22

There is little information concerning possible inter-
actions between the renin-angiotensin system and the 
pituitary-adrenal axis in hypertension. Recently Atlas 
and associates 26 reported that plasma cortisol concen-
tration at 0800 hours was higher in patients with high 
renin essential hypertension or renovascular hyperten-
sion than in patients with normal renin or low renin 
forms of hypertension. In the 36 patients studied, there 
as a significant correlation between plasma cortisol 
concentration and the log of PRA. Treatment with 
captopril caused a reduction in plasma cortisol concen-
tration in the patients with high renin but not in the 
normal or low renin groups. Angeli et al. 27 also mea-
sured plasma cortisol concentration in six patients with 
esential hypertension. Analysis of their data reveals a 
significant correlation between PRA and plasma corti-
sol concentration (r = 0.91, p < 0.01). They reported 
that plasma cortisol concentration did not change sig-
nificantly during treatment with captopril. Examina-
tion of their data, however, indicates that cortisol con-
centration did decrease in the three patients with high 
renin hypertension. Taken together, these observations 
indicate that in high renin forms of human hyperten-
sion, the renin-angiotensin system interacts with the 
pituitary-adrenal axis to influence the secretion of 
cortisol.

On the other hand, the present studies failed to 
reveal an interaction between the renin-angiotensin 
system and glucocorticoid secretion during the de-
velopment of renal hypertension in dogs. Plasma corti-
coiteroid concentration failed to increase even when 
PRA and plasma AII concentration had increased ten-
fold above their normal values. Acute blockade of the 
renin-angiotensin system with captopril or saralasin 
did not decrease corticosteroid concentration and, in 
some animals, corticosteroid levels actually increased, 
probably because of the fall in arterial pressure.

In summary, these results indicate that there may be 
an interaction between the renin-angiotensin system 
and vasopressin but not between the renin-angiotensin 
system and the pituitary-adrenal axis in the develop-
ment of renal hypertension in dogs. The results also 
indicate that the antihypertensive effect of captopril in 
this experimental model is not mediated via suppres-
ion of vasopressin, ACTH, or corticosteroid secretion.

Acknowledgments

The expert assistance of Roy Shackelford, Shirley Chi, and He-
en Hughes is gratefully acknowledged.

References

1. Laragh JH, Buhler FR, Seldin DW, eds. Frontiers in hyper-
tension research. New York: Springer-Verlag, 1981

Baltimore/Munich: Urban & Schwarzenberg, 1981

3. Reid JA, Brooks VL, Rudolph CD, Keil LC. Analysis of the 
actions of angiotensin on the central nervous system of con-
sic dogs. Am J Physiol 1982;243:R82-R91

In: Ganong WF, Martini L, eds. Frontiers in neuroendo-

5. Share L. Interrelations between vasopressin and the renin-

effects of exogenous and endogenous vasopressin at low plas-
ma concentrations in conscious dogs. Circ Res 1980;47:346-
355

7. Scoggin BA, Butkus A, Coghlan JP, Denton DA, Fan JSK, 
Humphrey TJ, Whidworth JA. Adrenocorticotrophic hormone-
induced hypertension in sheep: a model for the study of the 
effect of steroid hormones on blood pressure. Circ Res 1978;43 
(Suppl 1):I-76-81

8. Young DB. Comparison of a beta-blocker and converting en-
zyme inhibitor in two types of experimental hypertension. In: 
Laragh JH, Buhler FR, Seldin DW, eds. Frontiers in hyper-

9. Keil LC, Severs WB. Reduction in plasma vasopressin levels 
of dehydrated rats following acute stress. Endocrinology 
1977;106:30-38

10. Abraham GE, Manilimos FS, Garza R. Radioimmunoassay 
of steroids. In: Abraham GE, ed. Handbook of radioimmuno-

11. Stockigt JR, Collins RD, Bigheri EG. Determination of plas-
ma renin concentration by angiotensin I immunoassay. Dia-
nostic import of precise measurement of subnormal renin in 
hyperaldosteronism. Circ Res 1971;28 and 29 (Suppl II):II-
175-II-189

12. Reid IA, Stockigt JR, Goldfien A, Ganong WF. Stimulation of renin 
secretion in dogs by theophylline. Eur J Pharmacol 1972;17:325-332

13. Reid IA. The renin-angiotensin system. In: Radzialowski FM, 
ed. Hypertension research: methods and models. New York: 
Dekker, 1982:101-137

14. Winer BJ. Statistical principles in experimental design. New York: 
McGraw-Hill, 1971

15. Atkinson AB, Brown JJ, Fraser R, Lever AF, Morton JJ, 
Rieger AIG, Robertson JIS. Angiotensin II and renal hyper-
tension in dog, rat and man: effect of converting enzyme 


Role of the renin-angiotensin system in the control of vasopressin and ACTH secretion during the development of renal hypertension in dogs.

L K Ben, J Maselli, L C Keil and I A Reid

Hypertension, 1984;6:35-41
doi: 10.1161/01.HYP.6.1.35

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1984 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/6/1/35

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/